AstraZeneca: Imfinzi Shows Efficacy in Treating Small-Cell Lung Cancer
September 09 2019 - 4:27AM
Dow Jones News
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Monday that a phase 3 clinical
trial of drug Imfinzi showed the drug was able to improve survival
rates in patients with small-cell lung cancer.
The British pharmaceutical company said that Imfinzi combined
with chemotherapy showed a clinically meaningful improvement in
overall survival for patients with untreated extensive-stage
small-cell lung cancer when compared with standard
chemotherapy.
AstraZeneca said that the treatment reduced the risk of death by
27%, with a median overall survival of 13 months versus 10.3 months
for the standard of care.
In the study, titled Caspian, 33.9% of patients treated with
Imfinzi reached the 18-month survival mark, compared with 24.7% for
chemotherapy alone.
Small-cell lung cancer is an aggressive and fast-spreading
cancer.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
September 09, 2019 04:12 ET (08:12 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
